398 related articles for article (PubMed ID: 16314645)
21. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets.
Hirasawa A; Saito-Ohara F; Inoue J; Aoki D; Susumu N; Yokoyama T; Nozawa S; Inazawa J; Imoto I
Clin Cancer Res; 2003 Jun; 9(6):1995-2004. PubMed ID: 12796361
[TBL] [Abstract][Full Text] [Related]
22. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients.
Pan E; Pellarin M; Holmes E; Smirnov I; Misra A; Eberhart CG; Burger PC; Biegel JA; Feuerstein BG
Clin Cancer Res; 2005 Jul; 11(13):4733-40. PubMed ID: 16000568
[TBL] [Abstract][Full Text] [Related]
23. Molecular dissection of the chromosome band 7q21 amplicon in gastroesophageal junction adenocarcinomas identifies cyclin-dependent kinase 6 at both genomic and protein expression levels.
van Dekken H; van Marion R; Vissers KJ; Hop WC; Dinjens WN; Tilanus HW; Wink JC; van Duin M
Genes Chromosomes Cancer; 2008 Aug; 47(8):649-56. PubMed ID: 18438866
[TBL] [Abstract][Full Text] [Related]
24. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.
Kool M; Korshunov A; Remke M; Jones DT; Schlanstein M; Northcott PA; Cho YJ; Koster J; Schouten-van Meeteren A; van Vuurden D; Clifford SC; Pietsch T; von Bueren AO; Rutkowski S; McCabe M; Collins VP; Bäcklund ML; Haberler C; Bourdeaut F; Delattre O; Doz F; Ellison DW; Gilbertson RJ; Pomeroy SL; Taylor MD; Lichter P; Pfister SM
Acta Neuropathol; 2012 Apr; 123(4):473-84. PubMed ID: 22358457
[TBL] [Abstract][Full Text] [Related]
25. Hedgehog signaling drives medulloblastoma growth via CDK6.
Raleigh DR; Choksi PK; Krup AL; Mayer W; Santos N; Reiter JF
J Clin Invest; 2018 Jan; 128(1):120-124. PubMed ID: 29202464
[TBL] [Abstract][Full Text] [Related]
26. Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features.
Leonard JR; Cai DX; Rivet DJ; Kaufman BA; Park TS; Levy BK; Perry A
J Neurosurg; 2001 Jul; 95(1):82-8. PubMed ID: 11453402
[TBL] [Abstract][Full Text] [Related]
27. Type I collagen is overexpressed in medulloblastoma as a component of tumor microenvironment.
Liang Y; Diehn M; Bollen AW; Israel MA; Gupta N
J Neurooncol; 2008 Jan; 86(2):133-41. PubMed ID: 17653508
[TBL] [Abstract][Full Text] [Related]
28. EZH2-regulated DAB2IP is a medulloblastoma tumor suppressor and a positive marker for survival.
Smits M; van Rijn S; Hulleman E; Biesmans D; van Vuurden DG; Kool M; Haberler C; Aronica E; Vandertop WP; Noske DP; Würdinger T
Clin Cancer Res; 2012 Aug; 18(15):4048-58. PubMed ID: 22696229
[TBL] [Abstract][Full Text] [Related]
29. Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma.
Lo KC; Ma C; Bundy BN; Pomeroy SL; Eberhart CG; Cowell JK
Clin Cancer Res; 2007 Dec; 13(23):7022-8. PubMed ID: 18056178
[TBL] [Abstract][Full Text] [Related]
30. Cytogenetic evaluation of isochromosome 17q in posterior fossa tumors of children and correlation with clinical outcome in medulloblastoma. Detection of a novel chromosomal abnormality.
DeChiara C; Borghese A; Fiorillo A; Genesio R; Conti A; D'Amore R; Pettinato G; Varone A; Maggi G
Childs Nerv Syst; 2002 Aug; 18(8):380-4. PubMed ID: 12192498
[TBL] [Abstract][Full Text] [Related]
31. Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping.
Bayani J; Zielenska M; Marrano P; Kwan Ng Y; Taylor MD; Jay V; Rutka JT; Squire JA
J Neurosurg; 2000 Sep; 93(3):437-48. PubMed ID: 10969942
[TBL] [Abstract][Full Text] [Related]
32. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
[TBL] [Abstract][Full Text] [Related]
33. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients.
Lamont JM; McManamy CS; Pearson AD; Clifford SC; Ellison DW
Clin Cancer Res; 2004 Aug; 10(16):5482-93. PubMed ID: 15328187
[TBL] [Abstract][Full Text] [Related]
34. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor.
Yu J; Deshmukh H; Payton JE; Dunham C; Scheithauer BW; Tihan T; Prayson RA; Guha A; Bridge JA; Ferner RE; Lindberg GM; Gutmann RJ; Emnett RJ; Salavaggione L; Gutmann DH; Nagarajan R; Watson MA; Perry A
Clin Cancer Res; 2011 Apr; 17(7):1924-34. PubMed ID: 21325289
[TBL] [Abstract][Full Text] [Related]
35. Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D.
Castellino RC; De Bortoli M; Lu X; Moon SH; Nguyen TA; Shepard MA; Rao PH; Donehower LA; Kim JY
J Neurooncol; 2008 Feb; 86(3):245-56. PubMed ID: 17932621
[TBL] [Abstract][Full Text] [Related]
36. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.
Cho YJ; Tsherniak A; Tamayo P; Santagata S; Ligon A; Greulich H; Berhoukim R; Amani V; Goumnerova L; Eberhart CG; Lau CC; Olson JM; Gilbertson RJ; Gajjar A; Delattre O; Kool M; Ligon K; Meyerson M; Mesirov JP; Pomeroy SL
J Clin Oncol; 2011 Apr; 29(11):1424-30. PubMed ID: 21098324
[TBL] [Abstract][Full Text] [Related]
37. A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains.
Redon R; Muller D; Caulee K; Wanherdrick K; Abecassis J; du Manoir S
Cancer Res; 2001 May; 61(10):4122-9. PubMed ID: 11358835
[TBL] [Abstract][Full Text] [Related]
38. MiR-1253 exerts tumor-suppressive effects in medulloblastoma via inhibition of CDK6 and CD276 (B7-H3).
Kanchan RK; Perumal N; Atri P; Chirravuri Venkata R; Thapa I; Klinkebiel DL; Donson AM; Perry D; Punsoni M; Talmon GA; Coulter DW; Boue' DR; Snuderl M; Nasser MW; Batra SK; Vibhakar R; Mahapatra S
Brain Pathol; 2020 Jul; 30(4):732-745. PubMed ID: 32145124
[TBL] [Abstract][Full Text] [Related]
39. MiR-495 is a Predictive Biomarker that Downregulates GFI1 Expression in Medulloblastoma.
Wang C; Yun Z; Zhao T; Liu X; Ma X
Cell Physiol Biochem; 2015; 36(4):1430-9. PubMed ID: 26160036
[TBL] [Abstract][Full Text] [Related]
40. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
Tan DS; Lambros MB; Rayter S; Natrajan R; Vatcheva R; Gao Q; Marchiò C; Geyer FC; Savage K; Parry S; Fenwick K; Tamber N; Mackay A; Dexter T; Jameson C; McCluggage WG; Williams A; Graham A; Faratian D; El-Bahrawy M; Paige AJ; Gabra H; Gore ME; Zvelebil M; Lord CJ; Kaye SB; Ashworth A; Reis-Filho JS
Clin Cancer Res; 2009 Apr; 15(7):2269-80. PubMed ID: 19293255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
